ABSTRACT: Background. Detection of hypermethylated circulating tumor DNA has the potential to be a minimally invasive, low cost, and reproducible method for cancer detection. Methods. We evaluated serum from 100 patients with known head and neck squamous cell carcinoma (HNSCC) and 50 healthy control patients for 3 previously described methylation targets, endothelin receptor type B (EDNRB), cyclin-dependent kinase inhibitor 2A (CDKN2A or p16), and deleted in colorectal carcinoma (DCC), using quantitative methylation specific polymerase chain reaction (qMSPCR). Results. EDNRB hypermethylation was identified in the serum of 10% of the patients with HNSCC but in none of the control patients. DCC hypermethylation was detected in 2 serum samples from patients with cancer that also amplified EDNRB and one of these samples also had p16 hypermethylation. EDNRB hypermethylation was statistically significant by Fisher's exact test (p 5 .03) when comparing HNSCC to controls. Conclusions. Serum EDNRB hypermethylation is a highly specific but not sensitive serum biomarker for HNSCC.
INTRODUCTION
The identification of molecular markers in body fluids for cancer detection is an area of intense research because of the promise the panels of these biomarkers have for allowing the detection of a variety of solid tumors. Body fluids can carry whole cells, as well as protein, DNA, and RNA from tumors that can be readily identified by a variety of testing modalities. Examples of relevant body fluids used for detection include sputum for lung cancer diagnosis, 1,2 urine for renal and bladder cancers, 3 and saliva for head and neck squamous carcinoma (HNSCC), [4] [5] [6] breast fluid collected by fine-needle aspiration, 7 and serum. 8 Circulating biomarkers are attractive for cancer screening because they are blood-based tests that are minimally invasive, relatively low-cost, and easily repeatable.
An epigenetic pathway of transcriptional inactivation for many tumor-suppressor genes includes CpG island hypermethylation within promoter regions. 9, 10 This pathway has been identified in many different cancers and recent studies have focused on promoter hypermethylation in HNSCC. 11, 12 Promoter hypermethylation in tissue samples can be detected by using real-time quantitative methylation-specific polymerase chain reaction (qMSPCR). This methodology allows for an objective, robust, and rapid assessment of promoter methylation status. The ability to quantify methylation provides the potential for determination of a threshold level of methylation to improve sensitivity and specificity in detection of tumor-specific signals. [13] [14] [15] The detection of DNA methylation in body fluids also has the potential to distinguish high-risk subjects that harbor occult cancers and have a higher risk for development of solid tumors in a wide variety of human cancers. Based on our group's previous experience detecting aberrant methylation in salivary rinses, 16, 17 we conducted a study to investigate the ability of 3 of our most promising salivary detecting methylation probes to detect altered methylation in the serum of pretreatment of patients with HNSCC. Endothelin receptor type B (EDNRB), deleted in colorectal carcinoma (DCC), and cyclin-dependent kinase inhibitor 2A (CDKN2A or p16) were screened for hypermethylation in serum from patients with HNSCC and normal control volunteers.
MATERIALS AND METHODS

Serum samples
Samples were obtained from patients with HNSCC presenting with a previously untreated squamous cell carcinoma from the oral cavity, larynx, or pharynx. Patients were evaluated and enrolled in a research study protocol from 1994 to 2003 in the Department of Otolaryngology-Head and Neck Surgery at Johns Hopkins Medical Institutions, Baltimore, Maryland. Serum samples from these patients were collected before any cancer treatment, while the primary tumor was present. Patients were selected for candidacy for the study on the basis of the ability to provide adequate tumor sample, blood, salivary rinses, and availability for long-term follow-up. Serum samples from healthy patients were obtained through a head and neck cancer screening protocol. All individuals in the head and neck cancer screening protocol were called by telephone once a year after enrollment and interviewed to determine interval changes in tobacco and alcohol consumption and health history, including any new cancer diagnosis. Patients with premalignant oral cavity lesions, a history of any type of cancer, or who had developed any type of cancer at the 1-year follow-up were excluded from this study. Both experimental protocols were approved by the Johns Hopkins Medical Institutions Institutional Review Board and written informed consent was obtained from all enrolled subjects.
Sample selection
Samples were selected serum samples from 100 patients with HNSCC and 50 healthy, cancer-free controls for inclusion in this study from larger pools of previously collected samples. Every attempt was made to match both cohorts for age, sex, race, tobacco usage, and alcohol usage (Table 1) . Mean age was 58.3 years in the HNSCC group and 56.2 years in the control group, and the groups were well matched for race and sex. The sera were predominantly from white patients and there was a higher incidence of both smoking and tobacco usage in the cancer group. HNSCCs from the oral cavity, oropharynx, larynx, and hypopharynx were included, with oral cavity and oropharyngeal tumors most strongly represented.
DNA extraction
The blood was centrifuged at 2000 3 g for 10 minutes at room temperature, and 1 mL aliquots of serum/plasma samples were stored at 280 C. DNA extracted from the serum by digestion with 50 mg/mL proteinase K (Boehringer) in the presence of 1% sodium dodecyl sulfate at 48 C for 2 days, followed by phenol/chloroform extraction and ethanol precipitation, and finally dissolved in 30 to 60 mL of Tris-EDTA (2.5 mmol/L and 10 mmol/L Tris-hydrochloride).
Bisulfite treatment
Bisulfite conversion of 2 mg of genomic DNA from all samples was conducted using the Qiagen EpiTect bisulfite conversion kit using the manufacturer's protocol (Qiagen, Valencia, CA).
Target gene selection
Genes selected for this study, came from studies previously done by the authors to develop panels for early detection of HNSCC in other body fluids. 16, 17 EDNRB, DCC, and p16 hypermethylation probes were chosen based on previous specificity for HNSCC.
Quantitative methylation-specific polymerase chain reaction
The bisulfite-modified DNA was used as a template for fluorescence-based real-time polymerase chain reaction (PCR), as previously described. 18 In brief, primers and probes were designed to specifically amplify the bisulfiteconverted DNA for the b-actin gene (ACTB) and all genes of interest (primers and probes sequences are available on previous publications; DCC and p16 16 ; EDNRB 17 ). The ratios between the values of the gene of interest and the internal reference gene (ACTB), was obtained by Taqman analysis taking into account the PCR efficiency. Results were used as a measure of the relative quantity of methylation in a particular sample (value for the gene of interest/value for the reference gene 3100). 
Amplifications were carried out in 384-well plates in a 7900 Sequence Detector System (Perkin-Elmer Applied Biosystems). Thermal cycling was initiated with a first denaturation step at 95 C for 2 minutes, followed by 45 cycles at 95 C for 15 seconds and 60 C or 62 C for 1 minute. Leukocytes from a healthy individual were methylated in vitro with excess SssI methyltransferase (New England Biolabs) to generate completely methylated DNA, and serial dilutions of this DNA were used for constructing the calibration curves on each plate.
Each reaction was done in triplicate, the average of the triplicate was considered for analysis. Results for qMSPCR was analyzed considering the quantity of methylation (normalized to ACTB expression) and considering methylation as a binary event, in which any quantity of methylation in a sample would be considered as positive. Samples for which the ACTB control did not amplify were removed from the study and replaced with new samples.
Statistical analysis
Statistical analyses for qMSPCR results were performed using Stata 11 data analysis and statistical software (StataCorp, College Station, TX). Methylation levels of EDNRB, DCC, and p16 between healthy subjects and patients with HNSCC were compared using the Wilcoxon rank sum test and the frequency or marker presence was compared using Fisher's exact test.
Binary indicators of EDNRB, DCC, and p16 methylation in HNSCC salivary rinses were used to study their association with 2 time-to-event clinical outcomes: overall survival and local recurrence-free survival. Local recurrence-free survival time was defined as the time elapsed from the date of completion of therapy to the date of local recurrence. Death without local recurrence is censored at the time of death. Other factors, such as sex, tobacco exposure, human papillomavirus (HPV) positivity, primary site location, overall stage, as well as T and N classification, were also examined. For each prognostic factor, proportional hazards model was used to estimate the hazard ratio and the corresponding 95% confidence interval (CI). The p values were obtained from the logrank test. All tests were 2-sided with significance level set at 0.05.
RESULTS
Head and neck cancer and control patient characteristics
Patients with HNSCC were predominantly male (77%) and white (90%) with a median age of 58.3 years. Current or past tobacco and alcohol consumption was found in 100% of patients in the HNSCC cohort, compared to control patients in which 44% and 33% were nonsmokers and nondrinkers, respectively ( Table 1 ). The healthy control patients were more equally distributed among the sexes with only a small male predominance (58%), when compared to HNSCC samples in which 77% were men. Age and race were able to be closely matched in this study ( Table 1) .
Evaluation of methylation levels in serum samples
QMSPCR was conducted on all tumor and control samples using primer-probe pairs designed to detect hypermethylated EDNRB, DCC, and p16 genes. Detection of hypermethylation was interpreted in a binary fashion with any amplification being considered positive. Ten serum samples from patients with cancer had amplification of EDNRB. Two of these 10 samples also had amplified DCC. One of these 2 samples also had amplification of p16. There was no amplification of any of the genes in serum from healthy control patients (Figure 1 ). The expression levels of EDNRB was significantly higher among patients with cancer than controls (p 5 .02), but the difference was not significant with DCC or p16 (p 5 .32 and .48, respectively; Table 2 ). The ability of the EDNRB probe to differentiate between HNSCC and normal control serum samples was found to be statistically significant by Fisher's exact test (p 5 .03), however, neither DCC (p 5 .55) nor p16 (p 5 .99) were found to have statistical significance.
Interestingly, previous hypermethylation studies performed on primary tumors and oral salivary rinses from patients with HNSCC showed concordant results. Only 22 of the serum samples evaluated in this study were previously used to evaluate promoter hypermethylation in salivary rinses and tumors from the same patients with HNSCC. Nine of the 10 HNSCC serum samples that amplified EDNRB in this study also showed similar promoter hypermethylation in both primary tumor and salivary rinse samples from the same patients with HNSCC. Of the 12 remaining HNSCC serum samples from patients tested in previous studies, 6 failed to amplify EDNRB in serum, saliva, or tumor, 4 showed hypermethylation in both tumor and saliva but not serum, and 2 were positive in either the tumor or the saliva and not the serum samples. 16, 17 These preliminary results suggest that promoter hypermethylation found in body fluids may closely mirror the methylation changes in primary tumors.
Methylation and clinical outcomes
We examined the association of the serum methylation markers and various clinical outcomes with overall survival and local recurrence-free survival. As previously outlined, univariate analysis was conducted comparing the demographic characteristics of patients with cancer. The serum samples revealed a statistically significant association between decreased local recurrence-free survival and oral cavity primary tumor site (Table 3) , and improved overall survival and HPV positivity, oropharyngeal primary site, and low T classification, but no association with overall tumor stage or N classification (Table 4) . No significant association was found between local recurrence-free survival or overall survival and serum positivity for any of the EDNRB, DCC, and p16 hypermethylation probes (Tables 3 and 4) .
DISCUSSION
Aberrant promoter hypermethylation has been proposed as a means for detection of tumor-specific cells in body fluids and exfoliated cells in solid tumors, including HNSCC. In previous studies, we have evaluated a large sample size of both controls and patients with HNSCC by using an expanded panel of methylated promoter regions to determine the ability of qMSPCR to detect tumorspecific promoter methylation in salivary rinses. In this study, we evaluated 3 of the top genes identified from these studies to evaluate their ability to differentiate serum from cancer and healthy control patients. Given the sensitivity of the qMSPCR technique used to detect the presence of methylated alleles in a background of normal at a threshold of 1/1000 to 1/10,000, this strategy allowed us to differentiate serum from a subset of patients with cancer with 100% specificity. It has previously been shown that a combination of 3 or 4 genes is able to provide a sensitivity of cancer detection ranging from 24.0% to 35.1% with a specificity ranging from 90.0% to 97.1%. 16, 19 EDNRB proved to be the most specific probe with a specificity of 100%, but only recognized 10% of HNSCC samples. Interestingly, the addition of DCC and p16 probes did not improve the sensitivity of our study because they only amplified in samples that also had EDNRB hypermethylation. DCC and p16 were previously shown to have high specificity for HNSCC samples in oral rinses, 16 but this did not hold true for serum DNA, as shown in this study.
Interestingly, EDNRB promoter hypermethylation found in HNSCC serum samples mirrored those of both oral salivary rinses and primary tumor tissue from the same patients with HNSCC. 16, 17 Only a limited number of HNSCC serum samples used in this screening study were also used in previous studies looking at hypermethylation in HNSCC oral salivary rinses and primary tumor tissue, but it does suggest that once methylation changes occur in the tumor they may also be present in secreted body fluids of patients with HNSCC. These results are encouraging to continue the effort to actively identify and test potential HNSCC biomarkers in body fluids, which potentially can then be used for diagnostic and prognostic purposes. Further studies with larger sample sizes are needed to evaluate promoter hypermethylation changes in matched body fluid samples and primary tumors to help with these efforts.
The results of this screening study highlight the challenges of finding highly specific and sensitive markers for HNSCC as well as other solid tumors. As promoter hypermethylation patterns in individual tumors and even normal tissues show variation depending on specific altered molecular pathways, the use of multiple genes will provide greater applicability and coverage for diverse tumors when compared with a single gene for general detection use. This study was unable to increase the sensitivity by combining results from multiple probes but this is likely because of the overall low levels and frequency of hypermethylation in the HNSCC samples for the DCC and p16 probes.
This study had obvious limitation, including that the probes utilized did not investigate the complete promoter region, so the potential functional silencing of the gene is not necessarily associated with our detection of methylation. However, the purpose of this study was to evaluate performance of these probes as a screening tool rather than an indicator of functional alteration in primary tumors. These results also show that overall EDNRB, DCC, and p16 have high specificity but also low sensitivity, which would not be advantageous for populationbased screening. However, these results may have potential use for surveillance of a high-risk population or posttreatment patients with HNSCC. Finally, this was an exploratory study in a single cohort of patients. As with all screening and detection modalities, an optimum combination of genes for hypermethylation-based HNSCC detection needs to continue to be developed and then further validated in an independent cohort. In general, we were able to define EDNRB as a target for qMSPCR detection of HNSCC with a high degree of specificity but with an accompanied low sensitivity. All of our positive samples were stage IV cancers. This may be due to the fact that larger or more aggressive tumors have a higher degree of intratumor vascular irregularities that allow increased leakage of tumor DNA into serum. Additionally, more aggressive tumors are likely to have a higher burden of epigenetic alteration increasing the likelihood that hypermethylated DNA can be detected in these patients' serum.
CONCLUSION
We were able to confirm an elevated rate of promoter hypermethylation detected in the serum of patients with HNSCC by probing 3 gene promoters previously found to be hypermethylated in HNSCC but not in control subjects. We found that we were able to detect serum from patients with cancer with 100% specificity but low sensitivity using our probe for EDNRB. Further investigation is warranted to find additional serum methylation targets that can be used as a panel to increase the sensitivity of serum-based HNSCC screening. Serum-base screening has the potential to allow for earlier detection and treatment of HNSCC. New screening modalities for HNSCC are desperately needed, because, despite advances in surgical techniques and our understanding of the pathophysiology of HNSCC, overall survival has not increased in the past 30 years. 20 
